An update from Urogen Pharma (URGN) is now available.
UroGen Pharma Ltd. has shared promising results from its Phase 3 ENVISION trial for UGN-102, a potential treatment for low-grade non-muscle invasive bladder cancer. The trial met its primary endpoint, showing a high rate of complete response at three months, with many patients maintaining the response at 12 months. The company is progressing with a New Drug Application to the FDA, eyeing a potential market opportunity exceeding $5 billion for UGN-102. If approved, the treatment could offer a significant alternative to the current standard procedure, potentially improving patient outcomes and quality of life.
For a thorough assessment of URGN stock, go to TipRanks’ Stock Analysis page.
